Newsfeeds - Spark Newswire

2 minute read

News

Kadmon Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK(TM) In Chronic Graft-Versus-Host Disease

Today, 11:41 AM

Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that data from the pivotal ROCKstar clinical trial of REZUROCK™ (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) were published in the

KDMN

1 minute read

Kadmon’s REZUROCK Scores Quick FDA Win For Chronic Graft-Versus-Host Disease

By Vandana Singh

Today, 11:41 AM

Friday afternoon, the FDA approved Kadmon Holdings Inc’s (NASDAQ:KDMN) REZUROCK to treat chronic graft-versus-host disease (cGVHD), a serious complication of transplant…

KDMN

4 minute read

50 Biggest Movers From Friday

By Lisa Levin

Today, 11:41 AM

Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 41.2% to settle at $7.10 on Friday.

AACG

3 minute read

FDA
News

Kadmon Reports FDA Grants Full Approval Of REZUROCK For Treatment Of Patients With Chronic Graft Versus Host Disease

By Benzinga Newsdesk

Today, 11:41 AM

REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - - Kadmon to Host Conference Call on Monday,

KDMN

7 minute read

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes

By Shanthi Rexaline

Today, 11:41 AM

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.

ADAP

2 minute read

Uncategorized

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 11:41 AM

Gainers

ARDX

Latest news

Kadmon Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK(TM) In Chronic Graft-Versus-Host Disease

Kadmon’s REZUROCK Scores Quick FDA Win For Chronic Graft-Versus-Host Disease

50 Biggest Movers From Friday

Kadmon Reports FDA Grants Full Approval Of REZUROCK For Treatment Of Patients With Chronic Graft Versus Host Disease

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes

12 Health Care Stocks Moving In Thursday’s After-Market Session